BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 19030197)

  • 1. Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition.
    Iacobellis A; Ippolito A; Andriulli A
    World J Gastroenterol; 2008 Nov; 14(42):6467-72. PubMed ID: 19030197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension.
    Giannini EG; Basso M; Savarino V; Picciotto A
    J Intern Med; 2009 Dec; 266(6):537-46. PubMed ID: 19849774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antiviral treatment and long-term clinical outcome of decompensated cirrhotic patients with hepatitis C virus infection].
    Ji F; Dang S; Cai Z; Xue H; Huang N; Liu L; Zhang S; Guo Y; Jia X; Wang Y; Li Z; Deng H
    Zhonghua Gan Zang Bing Za Zhi; 2015 Sep; 23(9):647-52. PubMed ID: 26524356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
    Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral therapy in patients with HCV-cirrhosis.
    Melero J; Berenguer M
    Ann Hepatol; 2009; 8(4):292-7. PubMed ID: 20009127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis.
    Mira JA; García-Rey S; Rivero A; de los Santos-Gil I; López-Cortés LF; Girón-González JA; Téllez F; Márquez M; Merino D; Ríos-Villegas MJ; Macías J; Rivero-Juárez A; Pineda JA
    Clin Infect Dis; 2012 Dec; 55(12):1719-26. PubMed ID: 22955435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin.
    Perrakis A; Yedibela S; Schuhmann S; Croner R; Schellerer V; Demir R; Hohenberger W; Müller V
    Transplant Proc; 2011 Dec; 43(10):3824-8. PubMed ID: 22172854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation.
    Forns X; García-Retortillo M; Serrano T; Feliu A; Suarez F; de la Mata M; García-Valdecasas JC; Navasa M; Rimola A; Rodés J
    J Hepatol; 2003 Sep; 39(3):389-96. PubMed ID: 12927925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegylated interferon α-2a plus ribavirin for decompensated hepatitis C virus-related cirrhosis: relationship between efficacy and cumulative dose.
    Xu Y; Qi W; Wang X; Zhao P; Zhang Y; Zhang Q; Qin S; Wang J
    Liver Int; 2014 Nov; 34(10):1522-31. PubMed ID: 25453135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation.
    Nair S; Lipscomb J; Eason J
    Transplantation; 2008 Aug; 86(3):418-22. PubMed ID: 18698245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukocyte interferon alpha early retreatment for Child A HCV genotype 1b-infected cirrhotics intolerant to pegylated interferons.
    Cacopardo B; Nunnari G; Benanti F; Cappellani A; Onorante A; Caltabiano E; Russo R
    Infection; 2009 Jun; 37(3):210-5. PubMed ID: 19139808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: a randomised controlled study.
    Benetti G; Borzio M; Ramella G; Bellati G; Fargion S; Colombo A; Croce G; Iamoletti C; Balzola F; Rizzetto M;
    Intern Emerg Med; 2006; 1(2):113-8. PubMed ID: 17111783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of spleen operation on antiviral treatment in hepatitis C virus-related cirrhotic patients.
    Feng B; Zhang W; Luo BF; Song GJ; Wang J; Jin Q; Qin H; Wei L
    World J Gastroenterol; 2014 Nov; 20(41):15387-97. PubMed ID: 25386089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection].
    Cheong HR; Woo HY; Heo J; Yoon KT; Kim DU; Kim GH; Kang DH; Song GA; Cho M
    Korean J Hepatol; 2010 Mar; 16(1):38-48. PubMed ID: 20375641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virus.
    Gurusamy KS; Tsochatzis E; Toon CD; Xirouchakis E; Burroughs AK; Davidson BR
    Cochrane Database Syst Rev; 2013 Dec; 2013(12):CD006803. PubMed ID: 24307460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial.
    Di Marco V; Almasio PL; Ferraro D; Calvaruso V; Alaimo G; Peralta S; Di Stefano R; Craxì A
    J Hepatol; 2007 Oct; 47(4):484-91. PubMed ID: 17692985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation.
    Castells L; Vargas V; Allende H; Bilbao I; Luis Lázaro J; Margarit C; Esteban R; Guardia J
    J Hepatol; 2005 Jul; 43(1):53-9. PubMed ID: 15876467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy.
    Singal AG; Waljee AK; Shiffman M; Bacon BR; Schoenfeld PS
    Aliment Pharmacol Ther; 2010 Oct; 32(8):969-83. PubMed ID: 20937042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics.
    Tekin F; Gunsar F; Karasu Z; Akarca U; Ersoz G
    Aliment Pharmacol Ther; 2008 Jun; 27(11):1081-5. PubMed ID: 18346186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylated interferon alfa 2b and oral ribavirin in patients with HCV-related cirrhosis.
    Sood A; Midha V; Sood N; Bansal M
    Indian J Gastroenterol; 2006; 25(6):283-5. PubMed ID: 17264426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.